Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? Treatment decision-making in advanced disease

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GOSERELIN; IBANDRONIC ACID; LAPATINIB; LETROZOLE; METHOTREXATE; MITOMYCIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; PREDNISONE; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ANOREXIA; BREAST BIOPSY; BREAST CANCER; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CROSSOVER PROCEDURE; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATIENT DECISION MAKING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; DECISION MAKING; PATHOLOGY; PATIENT SATISFACTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; HUMANS; PATIENT SATISFACTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 53449086527     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn453     Document Type: Conference Paper

References (52)

1. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620-623.
2. Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004; 100: 44-52.
3. Chia SK, Speers CH, D'Yachkova Y et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-979.
4. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
5. Jassem J, Pienkowski T, Pluzanska A et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-1715.
6. Stewart DJ, Evans WK, Shepherd FA et al. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin. J Clin Oncol 1997; 15: 1897-1905.
7. Bishop JF, Dewar J, Toner GC et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17: 2355-2364.
8. Nabholtz A Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413-1424.
9. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
11. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
12. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2395-2405.
13. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
14. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
15. Coates AS, Hurny C, Peterson HF et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 2000; 18: 3768-3774.
16. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer - taking stock. J Natl Cancer Inst 2003; 95: 263-281.
17. Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 2002; 3: 620-628.
18. Kramer JA, Curran D, Piccart M et al. Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: Quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 2000; 36: 1488-1497.
19. Albain K. Global phase III study of gerricitabine plus paclitaxel vs paclitaxel as frontline therapy for metastatic disease for metastatic breast cancer: First report of overall survival. J Clin Oncol ASCO Annual Meeting Proc 2004; 22 (14S): (abstract 510).
20. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase III Study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol ASCO Annual Meeting Proc 2004; 22 (14S): (abstract 512).
21. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23: 2469-2476.
22. Lipton A, Leitzel K, Ali SM et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005; 104: 257-263.
23. ESMO. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). Ann Oncol 2005; 16: I10-i2.
24. NCCN. NCCN Clinical Practice Guidelines in Oncology - Breast Cancer V.2. http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf 2008.
25. NICE. Guidance on Cancer Services - Improving Outcomes in Breast Cancer: Manual Update. http://www.nice.org.uk/nicemedia/pdf/ Improving_outcomes_breastcancer_manual.pdf 2002.
26. Cavalli F, Beer M. Martz G et al. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J (Clin Res Ed) 1983; 286: 5-8.
27. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 1986; 4: 186-193.
28. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-2442.
29. Osbome CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
30. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
31. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-1613.
32. NCRN. SOFEA Study. http://publicukcrnorguk/Search/ StudyDetailaspx?StudyID=1190 2008.
33. Johnston SR, Martin LA, Leary A et al. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 2007; 106: 180-186.
34. Kaufman B. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC) European Society for Medical Oncology (ESMO) Congress 2006; (abstract LBA2).
35. Mackey J. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006; 100: (abstract 3).
36. Neville-Webbe HL, Holen I, Coleman RE. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002; 28: 305-319.
37. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-3224.
38. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-1137.
39. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003; 21: 588-592.
40. Banerji U, Kuciejewska A, Ashley S et al. Factors determining outcome after third line chemotherapy for metastatic breast cancer. Breast 2007; 16: 359-366.
41. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 1988; 6: 976-982.
42. Verrill MW, Lee J, Cameron DA et al. Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol ASCO Annual Meeting Proc 2007; 25 (18S): (abstract LBA1005).
43. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-51.
44. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759-1768.
45. Weber BL, Vogel C, Jones S et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722-2730.
46. Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology 2001; 15: 11-14.
47. Urruticoechea A, Archer CD, Assersohn LA et al. Mitomycin C, vinblastine and cisplatin (MVP): An active and well-tolerated salvage regimen for advanced breast cancer. Br J Cancer 2005; 92: 475-479.
48. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730.
49. Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-92.
50. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
51. Minckwitz G von VP, Schmidt M et al. Trastuzumab treatment beyond progression in patients with HER2 positive metastatic breast cancer- interim report. 30th Annual San Antonio Breast Cancer Symposium 2007; (abstract 4056).
52. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.